STOCK TITAN
  1. Home
  2. News
  3. GMDA

Gamida Cell Ltd - GMDA STOCK NEWS

Welcome to our dedicated news page for Gamida Cell (Ticker: GMDA), a resource for investors and traders seeking the latest updates and insights on Gamida Cell.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gamida Cell's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gamida Cell's position in the market.

News
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
Rhea-AI Summary
Gamida Cell announces a restructuring process with Highbridge Capital Management, converting $75 million of debt into equity and receiving $30 million in new capital. The company will become private, cancel outstanding shares, and issue contingent value rights. Omisirge® commercialization progresses with 17 transplant centers onboarded in 2023 and confirmed payer coverage exceeding 90%. Revenue for six units of Omisirge delivered in 2023. Positive data from Expanded Access Program and Phase 1 study of GDA-201 presented at conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-82.74%
Tags
earnings
-
News
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
Rhea-AI Summary
Gamida Cell (Nasdaq: GMDA) is set to receive significant new capital from Highbridge to enhance the commercialization of allogeneic stem cell transplant Omisirge®. The company will become private under Highbridge ownership post Israeli court approval. The restructuring agreement with Highbridge will provide Gamida Cell with a long-term financial runway, including a $30 million capital infusion and conversion of $75 million of Highbridge's existing note into equity. Gamida Cell will issue contingent value rights worth up to $27.5 million to ordinary shareholders. The transaction aims to support the ongoing efforts to make Omisirge available to more transplant centers and patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-82.74%
Tags
none
-
News
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
Gamida Cell (Nasdaq: GMDA) will release its financial results for Q4 and full year 2023 on March 27, 2024. The company will host a conference call and webcast to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
conferences earnings
News
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Rhea-AI Summary
Gamida Cell Ltd. presents promising data on omidubicel and GDA-201 cell therapies at the 2024 Tandem Meetings, showcasing positive outcomes in hematopoietic recovery and anti-tumor activity. Omidubicel's expanded access program aligns with Phase 3 results, demonstrating rapid recovery and low infection rates post-transplant. GDA-201 Phase 1 data reveal encouraging anti-tumor responses in non-Hodgkin lymphoma patients, with no severe adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
none
-
News
Gamida Cell Actively Pursuing Strategic Alternatives
Rhea-AI Summary
Gamida Cell Ltd. (Nasdaq: GMDA) is pursuing strategic alternatives to maximize value for stakeholders, focusing on an asset sale, merger, or other strategic transaction. The company also continues to prioritize the commercialization of Omisirge® (omidubicel-onlv), the first and only FDA-approved nicotinamide modified cell therapy donor source for allogeneic stem cell transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.78%
Tags
none
-
News
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Rhea-AI Summary
Gamida Cell Ltd. (Nasdaq: GMDA) to present new data on FDA approved Omisirge® and allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 at the 2024 Tandem Meetings. The meetings will take place virtually and in person at the Henry B. González Convention Center in San Antonio, Texas, February 21-24.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023
Rhea-AI Summary
Gamida Cell Ltd. (GMDA) to host virtual fireside chat with thought leader Dr. Gary Schiller, discussing allogeneic stem cell transplant and Omisirge®. Event details and replay information provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
conferences
-
News
Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
Gamida Cell Ltd. (Nasdaq: GMDA) to Present Corporate Highlights at Piper Sandler 35th Annual Healthcare Conference in New York, NY. The company's management team will participate in a fireside chat and be available for one-on-one meetings. Interested investors can contact their Piper Sandler representative for more information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.35%
Tags
conferences
-
News
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
Rhea-AI Summary
Gamida Cell Ltd. (Nasdaq: GMDA) reports initial revenue from Omisirge® (omidubicel-onlv) following FDA approval, with 17 transplant centers onboarded, exceeding 2023 targets. Market access efforts have achieved coverage with more than 90% of commercial lives and all top U.S. commercial payers. Revenue from 4-6 units projected for full year 2023. Lean launch effort to continue in 2024 due to resource constraints.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.29%
Tags
earnings
News
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Rhea-AI Summary
Gamida Cell Ltd. shared new data on the impact of their proprietary nicotinamide (NAM) technology on their allogeneic stem cell therapy omidubicel and investigational natural killer (NK) cell therapy candidate GDA-201. Omidubicel was approved by the U.S. FDA for allogeneic stem cell transplant. The data presented at the Society for Immunotherapy of Cancer’s Annual Meeting demonstrate the unique cellular composition of omidubicel and the active phenotype of GDA-201 NK cells expanded in the presence of NAM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock GMDA logo
Gamida Cell Ltd

Nasdaq:GMDA

GMDA Rankings

N/A Ranked by Market Cap
#4856 Ranked by Stock Gains
N/A Ranked by Dividends

GMDA Stock Data

4.34M
120.38M
11.58%
26.49%
7.53%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Israel
Jerusalem

About GMDA

gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.